Sandoz

Sandoz advances biosimilar portfolio with sixth major biosimilar file acceptance in less than one year Sandoz is seeking approval for all indications included in the reference product’s label Sandoz’ submission includes data from multiple clinical trials with over 800 patients … Read the full press release →

Holzkirchen, Germany, 18-Feb-2016 — /EuropaWire/ — Sandoz, together with leading global charity World Child Cancer (WCC), is pleased to announce a new health initiative in the Philippines, aimed at improving the standard of care for children suffering from cancer. Cancer survival … Read the full press release →

Sandoz continues to advance its biosimilars program: Regulatory submission for Sandoz’ proposed biosimilar pegfilgrastim accepted by the FDA Sandoz demonstrates commitment to oncology by seeking approval for its proposed biosimilar pegfilgrastim. Sandoz believes that the totality of evidence in its … Read the full press release →

Novartis strengthens multiple sclerosis focus with the addition of Ofatumumab to leading MS portfolio which includes Gilenya and investigational treatments BAF312 and CJM112 Ofatumumab is a fully human monoclonal antibody for relapsing remitting multiple sclerosis (RRMS) which targets CD20 and … Read the full press release →

Princeton, New Jersey, 30-7-2015 — /EuropaWire/ — Sandoz today announced the US market introduction of its budesonide inhalation suspension, a generic version of Pulmicort Respules® (budesonide) inhalation suspension 1 mg strength by AstraZeneca LP. Sandoz’s budesonide inhalation suspension product is indicated … Read the full press release →

Non-communicable diseases like asthma are rising rapidly in sub-Saharan Africa where healthcare systems are ill-prepared to cope1 – Zambia is ranked #1 in the world for mortality due to asthma2 Increasing the medical expertise of local healthcare professionals is a … Read the full press release →

Approximately 400 mothers and newborns die in Ethiopia each day1,2partly due to health workers’ limited knowledge in the area of obstetrics Enhancing medical knowledge and skills of health workers helps reduce maternal and newborn mortality Sandoz is committed to increasing … Read the full press release →

Holzkirchen, Germany, 6-2-2015 — /EuropaWire/ — Between 160,000 and 200,000 children are estimated to be diagnosed with childhood cancer and around 100,000 die from it each year. With proper diagnosis, treatment and drugs, most childhood cancers can be cured. In … Read the full press release →

Pivotal PIONEER study compared safety and efficacy of the two compounds in the prevention of neutropenia in patients with breast cancer PIONEER data supported filing for biosimilar filgrastim in the US The abstract of the study results is published online … Read the full press release →

Holzkirchen, 16-10-2014 — /EuropaWire/ — Sandoz is pleased to announce that Generics Bulletin, a newsletter covering commercial and regulatory information for the global generics industry, has awarded the company with “Biosimilars Initiative of the Year”, for its file acceptance of G-CSF … Read the full press release →

Munich, Germany, 28-3-2014 — /EuropaWire/ — Sandoz announced today that Vasant (Vas) Narasimhan, MD, MPP, has been appointed Head of Sandoz Biopharmaceuticals & Oncology Injectables effective April 1, 2014. Vas, currently Global Head of Development at Novartis Vaccines, succeeds Ameet Mallik who will … Read the full press release →

Holzkirchen, Germany, 31-1-2014 — /EuropaWire/ — Sandoz announced today it has received Romanian marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and COPD. The product was first approved in Denmark on December 18th, 2013. The new product … Read the full press release →

Princeton, New Jersey, 29-7-2013 — /EuropaWire/ — Sandoz announced today that the US Federal Circuit Court of Appeals has invalidated several patents asserted against the company by Teva Pharmaceuticals in litigation concerning a generic version of Copaxone® – one of the leading … Read the full press release →

Trial expected to support registration in the U.S. and European Union Sandoz continues to advance biosimilar pipeline with seven Phase III trials across five molecules Global program underscores Sandoz’s leadership in biosimilars Holzkirchen, Germany, 1-7-2013 — /europawire.eu/ — Sandoz, the global … Read the full press release →

Princeton, New Jersey, 5-3-2013 — /europawire.eu/ — Sandoz today announced the US launch of an authorized generic version of Eagle Pharmaceuticals’ ready-to-use argatroban injection 50 mg/50mL, aqueous solution (1 mg/mL). Argatroban injection is indicated for prophylaxis or treatment of thrombosis in adult … Read the full press release →

Brussels, 31-1-2013 — /europawire.eu/ — Following its competition inquiry into the pharmaceutical sector of 2008/2009 (see IP/09/1098 and MEMO/09/321) the European Commission has issued statements of objections against pharmaceutical companies in three major cases concerning citalopram, an antidepressant, (see IP/12/834), perindopril, a cardio-vascular medicine (see IP/12/835), and … Read the full press release →

Group net sales up 2% in constant currencies[1] (cc) in fourth quarter despite patent expirations; flat (cc) over full year Fourth quarter net sales reached USD 14.8 billion (0%, +2% cc); full year net sales were USD 56.7 billion (-3%, … Read the full press release →

Pharmaceuticals Division growth over the next 5 years expected to bedriven by portfolio of recently launched products Division had 7 blockbusters in portfolio in 2011 and expects to achieve 14 or more blockbusters by 2017 Industry-leading Pharmaceuticals pipeline with 73 … Read the full press release →

Holzkirchen, Germany, 3-11-2012 — /europawire.eu/ — Sandoz, the global leader in biosimilars, has started patient enrolment in a late stage clinical trial in the United States for its biosimilar epoetin alfa. The Phase III study will compare safety and efficacy of … Read the full press release →